A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

ConditionCutaneous Sarcoidosis

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorPriovant Therapeutics, Inc.

About this trial

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Eligibility criteria

Qualifiers

Adults subjects (18-74)

Cutaneous sarcoidosis with characteristic skin biopsy histology

A CSAMI activity score ≥ 10

Weight > 40 kg to < 130 kg with BMI < 40 kg/m2 .

Disqualifiers

History of

Lymphoproliferative disorder

Active malignancy;

History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).

Trial design

Treatments tested in this trial

Oral Brepocitinib
Oral Placebo

Treatment groups

28 Participants

are divided into 3 treatment groups

Sponsors and collaborators

Priovant Therapeutics, Inc.

Lead sponsor

Source ClinicalTrials.gov